紫杉醇联合FOLFOX4方案治疗晚期胃癌的临床观察  

Clinical observation of paclitaxel plus FOLFOX4 regimen for treatment of advanced gastric cancer

作　　者：贾锋[1] 孙雷[1] 李爱莲[1] 侯美英[1] 刘元建[1] 李亭山[1] 

机构地区：[1]济宁医学院附属金乡人民医院,山东济宁272200

出　　处：《中国肿瘤临床与康复》2009年第6期531-533,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察并比较紫杉醇联合FOLFOX4方案与FOLFOX4方案治疗晚期胃癌的疗效及毒副反应。方法随机将晚期胃癌患者分为两组,A组32例,采用紫杉醇联合FOLFOX4方案化疗;B组31例,采用FOLFOX4方案化疗。每2周重复,28d为1周期,每例患者至少完成2周期以上的化疗。结果A组有效率(CR+PR)为43.7%,中位疾病进展时间5.87个月,中位生存期9.8个月;B组有效率(CR+PR)为35.5%,中位疾病进展时间3.9个月,中位生存期8.5个月。两组有效率差异无显著性(P>0.05),中位疾病进展时间及中位生存期差异均有显著性(P<0.05)。两组主要毒副反应为白细胞下降、脱发、肌肉关节痛,两组发生率比较差异具有显著性(P<0.05)。结论紫杉醇联合FOLFOX4方案治疗晚期胃癌具有良好的疗效和耐受性。Objective To compare the efficacy and toxicity of paclitaxel plus FOLFOX4 regimen and FOLFOX4 regimen in the treatment of patients with advanced gastric carcinoma （AGG）. Methods A total of 63 patients with AGC were randomized into two groups. Two or more cycles of chemotherapy were completed. Group A consisted of 32 patients who received paclitaxel plus FOLFOX4 regimen and group B consisted of 31 patients who received FOLFOX4 regimen. Results The response rates （CR ＋ PR） of groups A and B were 43.7% and 35.5% , the median TTP was 5.87 and 3.9 months, and the median survival time of patients was 9. 8 and 8. 5 months, respectively. The response rates of the 2 groups had no significant difference （ P 〉 0. 05 ）. The median TFP and the median survival time had significant difference （ P 〈 0. 05 ）. The major side effect of the two groups had significant difference （P 〈 0.05 ）. Conclusion Paclitaxel plus FOLFOX4 regimen is an effective, acceptable and safe method for treatment of patients with advanced gastric cancer.

关 键 词：胃肿瘤/化学疗法 紫杉醇 奥沙利铂 氟尿嘧啶 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]